Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Postmarket Drug Safety Pilot Will Consider Between Five And 10 Drugs

Executive Summary

FDA expects to begin in March to develop the first safety profile under a pilot program for postmarket monitoring of new molecular entities
Advertisement

Related Content

FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
Two Postmarket NME Safety Reviews Done; Five To Be Finished By Early ’08
Two Postmarket NME Safety Reviews Done; Five To Be Finished By Early ’08
Post-Market Safety Pilot Begins With Reassessment Of Four NMEs By FDA
Post-Market Safety Pilot Begins With Reassessment Of Four NMEs By FDA
FDA To Re-Evaluate Safety Of NMEs In Pilot Postmarket Monitoring Program
FDA To Re-Evaluate Safety Of NMEs In Pilot Postmarket Monitoring Program
Advertisement
UsernamePublicRestriction

Register

PS048016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel